Allist Pharmaceuticals

About Allist Pharmaceuticals

Shanghai Allist Pharmaceuticals Co., Ltd. (STAR: 688578) is a publicly traded pharmaceutical company focused on the discovery, development, manufacturing, and commercialization of new medicines, with a strategic concentration on oncology. The company was established in March 2004, co-founded by entrepreneur Du Jinhao and Dr. Guo Jianhui, a former tenured scientist at the U.S. National Institutes of Health (NIH). This partnership combined business acumen with deep scientific expertise, aiming to address unmet clinical needs in the global market.

Dr. Guo, who held a Ph.D. from the Academy of Military Medical Sciences and conducted research in genetics and molecular biology in the U.S., provided the foundational scientific leadership. Following Dr. Guo's passing in 2012, Mr. Du Jinhao assumed full leadership, steering the company's strategic pivot towards oncology, specifically lung cancer treatments. A pivotal moment in the company's history was the 2012 transfer of its first approved innovative drug, the antihypertensive Allisartan Isoproxil, which provided significant capital to fuel its new focus on cancer therapies.

Allist operates an integrated business model that encompasses the entire drug lifecycle, from preclinical research and clinical trials to manufacturing and commercialization. Its revenue is generated through the sale of its pharmaceutical products and technology licensing agreements. A key product is Furmonertinib, a third-generation EGFR tyrosine kinase inhibitor (TKI) developed for the treatment of non-small cell lung cancer (NSCLC) with specific EGFR mutations. The company manages its commercialization through an in-house marketing and sales team that covers a vast network of hospitals and pharmacies across China. To expand its global reach, Allist entered a strategic licensing agreement with ArriVent Biopharma, granting them exclusive rights to develop and commercialize Furmonertinib outside of greater China in exchange for significant milestone payments and royalties.

The company's primary market is oncology therapeutics, serving patients with specific cancer types, particularly NSCLC. After operating for 15 years primarily through self-funding, the company secured its first major external financing with Series A and A+ rounds in 2019, which preceded its successful IPO on the Shanghai Stock Exchange's STAR market on December 2, 2020. Allist continues to expand its pipeline through in-house R&D and strategic in-licensing, such as its 2024 agreement with Jacobio Pharma for the China rights to KRAS G12C and SHP2 inhibitors, positioning itself as a key player in the targeted cancer therapy market.